Department of Pediatrics, All India Institute of Medical Science, Jodhpur, India.
Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, India.
Expert Rev Anti Infect Ther. 2022 Jul;20(7):1049-1059. doi: 10.1080/14787210.2022.2071702. Epub 2022 May 10.
Evidence from the basic research and epidemiological studies indicates a beneficial effect of vitamin D in the treatment of tuberculosis (TB). However, the evidence from randomized controlled trials (RCTs) is inconsistent.
This systematic review and meta-analysis was performed to synthesize evidence regarding role of vitamin D versus placebo for the management of TB.
We searched PubMed and Cochrane Clinical Trial Registry for RCTs comparing vitamin D versus placebo for the treatment of TB. RCTs enrolling adult patients with TB receiving vitamin D in addition to standard treatment were included. Data were pooled using random effects model. The study was conducted according to PRISMA guidelines and protocol was registered with PROSPERO (CRD42016052841).
Of 605 identified references, 12 RCTs were included. The overall risk of bias in included studies was low or unclear. There was no significant difference between vitamin D and placebo group for any outcomes of efficacy (time to culture conversion, time to smear conversion, rate of culture conversion, and rate of smear conversion) or safety (mortality, serious adverse events, and nonserious adverse events).
Vitamin D administered with standard treatment has no beneficial effect in the TB patients as compared to the placebo.
基础研究和流行病学研究的证据表明维生素 D 对治疗结核病（TB）有益。然而，随机对照试验（RCT）的证据并不一致。
本系统评价和荟萃分析旨在综合关于维生素 D 与安慰剂治疗 TB 的作用的证据。
我们在 PubMed 和 Cochrane 临床试验注册中心搜索了比较维生素 D 与安慰剂治疗 TB 的 RCT。纳入了在标准治疗的基础上额外给予维生素 D 的成年 TB 患者的 RCT。使用随机效应模型汇总数据。该研究按照 PRISMA 指南进行，并在 PROSPERO（CRD42016052841）进行了方案注册。
在 605 篇鉴定文献中，纳入了 12 项 RCT。纳入研究的总体偏倚风险较低或不明确。维生素 D 组与安慰剂组在疗效（培养物转换时间、涂片转换时间、培养物转换率和涂片转换率）或安全性（死亡率、严重不良事件和非严重不良事件）的任何结局方面均无显著差异。
与安慰剂相比，标准治疗联合维生素 D 治疗对 TB 患者没有有益效果。
